Ailar Tupal1, Mehdi Sabzichi2, Fatemeh Ramezani3, Maryam Kouhsoltani4, Hamed Hamishehkar5. 1. a Biotechnology Research Center and Faculty of Pharmacy , Tabriz University of Medical Sciences , Tabriz , Iran ; 2. b Research Center for Pharmaceutical Nanotechnology and Students' Research Committee , Tabriz University of Medical Sciences , Tabriz , Iran ; 3. c Department of Biochemistry , School of Medicine, Shiraz University of Medical Sciences , Iran ; 4. d Department of Oral & Maxillofacial Pathology, Faculty of Dentistry , Tabriz University of Medical Science , Tabriz , Iran ; 5. e Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
Abstract
OBJECTIVE: Dermal delivery of Doxorubicin (Dox) would be an ideal way in maximising drug efficiency against skin cancer accompanying with minimising side effects. We investigated the potential of Dox-loaded Solid lipid nanoparticles (SLNs) for topical delivery against skin cancer. METHODS: In vitro and in vivo cytotoxicity of optimised formulation were evaluated on murine melanoma (B16F10) cells by MTT assay and melanoma induced Balb/C mice, respectively. Animal study followed by histological analysis. RESULTS: Optimised formulation showed mean particle size and encapsulation efficiency (EE) of 92 nm and 86% w/w (0.86% w/w value of encapsulated Dox in the lipid matrix), respectively. FTIR experiment confirmed drug-lipid interaction interpreting the observed high EE value for Dox. In vitro and in vivo results indicated the superiority of cytotoxic performance of Dox-loaded SLN compared to Dox solution. CONCLUSION: Our findings may open the possibilities for the topical delivery of Dox to the skin cancerous tissues.
OBJECTIVE: Dermal delivery of Doxorubicin (Dox) would be an ideal way in maximising drug efficiency against skin cancer accompanying with minimising side effects. We investigated the potential of Dox-loaded Solid lipid nanoparticles (SLNs) for topical delivery against skin cancer. METHODS: In vitro and in vivo cytotoxicity of optimised formulation were evaluated on murinemelanoma (B16F10) cells by MTT assay and melanoma induced Balb/C mice, respectively. Animal study followed by histological analysis. RESULTS: Optimised formulation showed mean particle size and encapsulation efficiency (EE) of 92 nm and 86% w/w (0.86% w/w value of encapsulated Dox in the lipid matrix), respectively. FTIR experiment confirmed drug-lipid interaction interpreting the observed high EE value for Dox. In vitro and in vivo results indicated the superiority of cytotoxic performance of Dox-loaded SLN compared to Dox solution. CONCLUSION: Our findings may open the possibilities for the topical delivery of Dox to the skin cancerous tissues.
Authors: Harshita Mishra; Pawan K Mishra; Adam Ekielski; Manu Jaggi; Zeenat Iqbal; Sushama Talegaonkar Journal: J Cancer Res Clin Oncol Date: 2018-08-09 Impact factor: 4.553
Authors: Hadi Chavoshi; Vahid Vahedian; Somaiyeh Saghaei; Mohammad Bagher Pirouzpanah; Mortaza Raeisi; Nasser Samadi Journal: Asian Pac J Cancer Prev Date: 2017-08-27
Authors: Shaloam Dasari; Clement G Yedjou; Robert T Brodell; Allison R Cruse; Paul B Tchounwou Journal: Nanotechnol Rev Date: 2020-12-31 Impact factor: 7.848